Title: Severe Label Expansion for EVO Positioner (SLEEP) Study Description: Single-arm study to determine the safety and effectiveness of treating severe obstructive sleep apnea using the EVO Sleep and Snore Device (ProSomnus Sleep Technologies, Pleasanton, CA). Objectives: To determine the safety and effectiveness of the EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea. Endpoints: The primary effectiveness endpoint is the Sher criteria defined as a reduction of Apnea-Hypopnea Index (AHI) of at least 50% from the baseline value and a post-treatment AHI of less than 20 events/hour at 6 months following initiation of Oral Appliance Therapy (OAT) titration. AHI will be collected using HSAT at baseline and 6 months. The primary safety objective is to evaluate safety by summarizing all reported device and/or procedure related adverse events from the time the EVO device is introduced through 6 months. Study Population: A maximum of 49 individuals over the age of 18 years with severe obstructive sleep apnea will be enrolled. Description of Sites/Facilities Enrolling Participants: The study will be conducted at up to four sites, up to two of which could be located outside of the US. Description of Study Device: The study device is the EVO Sleep and Snore Device (ProSomnus Sleep Technologies, Pleasanton, CA). The device is a mandibular repositioning device used to treat obstructive sleep apnea. The device is currently cleared for the treatment of mild and moderate OSA. Study Duration: The time from when the study opens to enrollment until completion of data analyses is estimated to be 15 months.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
49
ProSomnus EVO Sleep and Snore Device mandibular advancement device
Mount Sinai Integrative Sleep Center
New York, New York, United States
RECRUITINGStar Sleep and Wellness
Dallas, Texas, United States
RECRUITINGSher responder rate endpoint
Proportion of participants who meet the Sher criteria at outcome, defined as a reduction of apnea-hypopnea index less than 20 events/hour and 50% or greater reduction from the baseline value.
Time frame: 6 months
Incidence of adverse events
Evaluation of safety by summarizing all reported device- and/or procedure-related adverse events from the time the EVO device is introduced through 6 months.
Time frame: 6 months
Sleep apnea-specific hypoxic burden
Proportion of participants achieving a sleep apnea-specific hypoxic burden less than 60 %min/h at 6 months
Time frame: 6 months
Epworth Sleepiness Scale change from baseline
Change in Epworth Sleepiness Scale from baseline to 6 months. The Epworth Sleepiness Scale ranges from 0 to 24, with 0 being the lowest and 24 being the highest score indicating propensity for sleep.
Time frame: 6 months
Sher criteria responder rate point estimate
Responder rate point estimate for the Sher criteria post-titration and at 6 months
Time frame: 6 months
Severity classification change
OSA severity classification change from baseline to post-titration and 6 months
Time frame: 6 months
Apnea-hypopnea index change from baseline
Change in AHI, ODI and SASHB change from baseline to 6 months
Time frame: 6 months
Oxygen desaturation index change from baseline
Change in oxygen desaturation index from baseline to 6 months
Time frame: 6 months
Sleep apnea-specific hypoxic burden change from baseline
Change in sleep apnea-specific hypoxic burden from baseline to 6 months
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.